Consultant in Metabolic Bone Diseases

NHS Contact Details

rno-tr.metabolicsecretary@nhs.net

020 3947 0056

Rheumatology

Osteoporosis and Metabolic bone diseases including CRMO/SAPHO, Fibrous dysplasia, Fibrodysplasia Ossificans Progressiva, Hypophosphatasia, Osteogenesis Imperfecta, Paget’s disease, Vitamin D deficiency and X-linked hypophosphataemic rickets.

Novel treatments for patients with rare bone diseases

Developing care pathways for patients with rare bone diseases

Understanding the pathogenesis and impact of rare bone diseases

Dr Bubbear is a Consultant Rheumatologist with a special interest in Metabolic Bone Disease. She was a Consultant at Barts Health for 7 years from 2010 and was appointed as a Consultant in Metabolic Bone Disease at the Royal National Orthopaedic Hospital in 2017.  She runs clinics for patients with Osteoporosis and Metabolic Bone Diseases at RNOH.  The metabolic diseases she has an interest in include CRMO/SAPHO, Fibrous dysplasia, Fibrodysplasia Ossificans Progressiva, Hypophosphatasia, Osteogenesis Imperfecta, Paget’s disease, Vitamin D deficiency and X-linked hypophosphataemic rickets.

Dr Bubbear did her pre-clinical medical training at Christ’s College, University of Cambridge graduating in 1996.  She completed her clinical training at University College London in 1999.  She completed her general medical training in London and her specialist rheumatology training in the North Thames rotation. 

During her rheumatology training, she developed an interest in metabolic bone diseases.  Her MD research was conducted at RNOH and was into Osteoporosis in patients with Spinal Cord Injuries. 

American Society of Bone and Mineral Research

Bone Research Society

British Society of Rheumatology

Royal Osteoporosis Society

Royal College of Physicians

Physical function and physical activity in adults with X-linked hypophosphatemia.

Orlando G, Bubbear J, Clarke S, Keen R, Roy M, Anilkumar A, Schini M, Walsh JS, Javaid MK, Ireland A.Osteoporos Int. 2022 Feb 5. doi: 10.1007/s00198-022-06318-w. Online ahead of print.

Patient-Reported Complications, Symptoms, and Experiences of Living With X-Linked Hypophosphatemia Across the Life-Course.

Cheung M, Rylands AJ, Williams A, Bailey K, Bubbear J.

J Endocr Soc. 2021 Apr 23;5(8):bvab070.

Update on the management of hypophosphatasia.

Choida V, Bubbear JS.

Ther Adv Musculoskelet Dis. 2019 Aug 1;11:1759720X19863997. 

Teriparatide and vertebral fracture healing in Ankylosing Spondylitis.

Biro I, Bubbear J, Donnelly S, Fattah Z, Sarkodieh J, Ranganathan A, Tahir H.

Trauma Case Rep. 2017 Nov 8;12:34-39.

Atypical Femur Fractures in Patients Treated with Bisphosphonates: Identification, Management, and Prevention.

Bubbear JS.

Rambam Maimonides Med J. 2016 Oct 31;7(4):e0032.

Early treatment with zoledronic acid prevents bone loss at the hip following acute spinal cord injury.

Bubbear JS, Gall A, Middleton FR, Ferguson-Pell M, Swaminathan R, Keen RW.

Osteoporos Int. 2011 Jan;22(1):271-9.

Molecular analysis of DMP1 mutants causing autosomal recessive hypophosphatemic rickets.

Farrow EG, Davis SI, Ward LM, Summers LJ, Bubbear JS, Keen R, Stamp TC, Baker LR, Bonewald LF, White KE.

Bone. 2009 Feb;44(2):287-94.

New guidelines for corticosteroid-induced osteoporosis.

Bubbear JS, Keen RW.

Rheumatology (Oxford). 2004 May;43(5):676-7.

Clinical management and algorithms in osteoporosis.

Bubbear J, Keen R.

Hosp Med. 2003 Sep;64(9):512-6.